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Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor
alpha (FR-α) has already been identified as a suitable target for cancer therapy and
imaging. FR-α is present on ~40% of human cancers. FR-β is known to be expressed on
several hematologic malignancies and on activated macrophages, but little is known about
FR-β expression in solid tumors. Additional or simultaneous expression of FR-β could help
extend the indications for folate-based drugs and imaging agents. In this study, the expres-
sion pattern of FR-β is evaluated in ovarian, breast and colorectal cancer.
Methods
FR-β expression was analyzed by semi-quantitative scoring of immunohistochemical stain-
ing on tissue microarrays (TMAs) of 339 ovarian cancer patients, 418 breast cancer
patients, on 20 slides of colorectal cancer samples and on 25 samples of diverticulitis.
Results
FR-β expression was seen in 21% of ovarian cancer samples, 9% of breast cancer sam-
ples, and 55% of colorectal cancer samples. Expression was weak or moderate. Of the
diverticulitis samples, 80% were positive for FR-β expression in macrophages. FR-β status
neither correlated to known disease-related variables, nor showed association with overall
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survival and progression free survival in ovarian and breast cancer. In breast cancer, nega-
tive axillary status was significantly correlated to FR-β expression (p=0.022).
Conclusions
FR-β expression was low or absent in the majority of ovarian, breast and colorectal tumor
samples. From the present study we conclude that the low FR-β expression in ovarian and
breast tumor tissue indicates limited practical use of this receptor in diagnostic imaging and
therapeutic purposes. Due to weak expression, FR-β is not regarded as a suitable target in
colorectal cancer.
Introduction
The folate receptor (FR) has been proposed as a target in cancer therapy and imaging. The vita-
min folate (B9) and its synthetic form folic acid, are indispensable for nucleotide synthesis.
Under physiologic conditions, uptake of folate occurs mostly through the reduced folate carrier
(RFC), which is sufficient in healthy tissues despite its fairly low affinity for folate [1]. Further-
more, some healthy tissues and a number of pathologic processes express the transmembrane
FR which has in the past two decades attracted attention as a target for diagnostic and thera-
peutic compounds because of its much higher affinity for folate [2].
The FR gene family includes four isoforms: FR-α, FR-β, FR-δ and FR-γ. The latter two play
a role in regulatory T-cells and fall outside the scope of this article. FR-α is expressed on the
apical side of a number of epithelial cells and is present on ~40% of solid tumors. Expression
varies between tumors, showing high expression in serous ovarian cancer and renal carcinoma
versus low to moderate expression in breast, colorectal and lung cancer [3–5]. The value of FR-
α targeting in cancer diagnosis and therapy has been shown using folate-conjugated imaging
agents as well as folate-based drugs [6–8].
Little is known regarding the expression of FR-β in solid tumors. Studies using mRNA isola-
tion and isolation of cellular membranes demonstrated expression on activated but not resting
macrophages, as well as on the surfaces of malignant cells of hematopoietic origin such as acute
leukemia [9,10]. Targeting of FR-β has shown to be feasible in the visualization of inflamma-
tory processes in rheumatoid arthritis and atherosclerosis [2,8,11].
Thus far, it is largely unknown whether FR-β is also expressed on solid tumors, apart from
one article stating that this may indeed be the case [6]. However, one study indicates that FR-β
mRNA can be found in tumors suggesting that FR-βmay play a role in tumor cell growth
and metastasis. It is suggested that the mechanism of action is mainly via infiltration of tumor-
associated macrophages (TAMs), which are guided towards the tumor by cytokines and are
thought to induce a more malignant tumor behavior [12]. It has furthermore been suggested
that folate-based immunotherapy for cancer may also exert its effect by targeting TAMs.
The overexpression of FR-α and/or FR-β on cancer cells and myelogenous cells allows for
both non-invasive diagnostic imaging of FR-positive cancers and inflammatory processes,
and subsequent treatment using folate-based drugs or FR-targeting antibodies. For instance,
discrimination could be made between a sigmoidal malignant neoplasm and diverticulitis.
However, the limited and variable expression of FR-α on solid tumors is a major restriction for
FR-targeted approaches. Additional or simultaneous expression of FR-β could help extend the
indications. The aim of this study is to investigate the expression pattern of FR-β in ovarian,
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breast and colorectal tumors, and thereby evaluate the possibilities and limitations for cancer
specific imaging and therapy in these cancer types.
Materials and Methods
Patient tissue samples
All study specimens were collected from our own archives of the Department of Pathology and
Medical Biology at the University Medical Center Groningen (UMCG). Tissue microarrays
(TMAs) of ovarian cancer (339 cases) and breast cancer (418 cases) were available from earlier
studies, including full databases of anonymized patient data. All TMAs were constructed in the
UMCG as described before [13,14], and consisted of 4 cores per patient. Furthermore, twenty
patient tumor samples of colorectal cancer were selected, all collected during cytoreductive
sugery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Twenty-five
patient samples of diverticulitis were selected based on postoperative pathology reports. Patient
data were retrieved from the electronic hospital patient data system and from the Dutch
Pathology Registry (PALGA). All patient data were anonymized and all studies concerning this
databank were conducted in accordance with the rules and regulations posed by our institu-
tional medical ethical research board; [The Medical Ethical Committee (in Dutch: Medisch
Ethische Toetsingsingscommissie or METc) of the University Medical Center Groningen
(UMCG)] which approved the study. Since we used archival pathology material, which does
not interfere with patient care and does not involve the physical involvement of the patient, no
ethical approval is required according to Dutch legislation [the Medical Research Involving
Human Subjects Act (Wet medisch-wetenschappelijk onderzoek met mensen, WMO [15])],
and as such informed consent was not required.
Sample preparation and immunohistochemistry
FR-β expression was determined by immunohistochemistry (IHC). The antibody for FR-β
staining (anti-human FR-β; Biotin-m909) was kindly provided by professor P.S. Low (Purdue
University, West Lafayette, IN, USA). TMAs were cut into 3 μm sections and fixed on glass
slides. All specimens were fixed by 10% formalin and embedded in paraffin. The samples were
rinsed well in distilled water after the formalin-fixed, paraffin-embedded (FFPE) samples were
deparaffinized with 3 changes of xylene and rehydrated in a series of alcohols. Antigen retrieval
was achieved by placing the slices in a preheated Target Retrieval Solution (Dako, Glostrup,
Denmark) for 5 minutes at 125°C then cooled in the buffer for 20 minutes to 90°C followed by
a 5 minute rinse in running phosphate buffered saline (PBS). Subsequently, sections were incu-
bated with 0.3% H2O2 in PBS for 30 minutes to inactivate the endogenous peroxidases. Slides
were rinsed well and then incubated for 3 hours at room temperature with the Biotinylated- hu
@ hu FR-β at a 1:100. After washing with PBS, the sections were incubated with peroxidase
labeled streptavidin (Thermo Scientific, Waltham, MA, USA and Dako) for 30 minutes. To
visualize peroxidase activity, the sections were incubated in 3,3-diaminobenzidine (DAB+) for
10 minutes. Subsequently, sections were counterstained with haematoxylin, mounted with a
permanent mounting media and coverslipped. Placental tissue was used as a positive control,
as earlier studies have described that placental villous stroma tissue should be positive [16]. In
addition tissue macrophages should be positive for FR-β, so they served as internal positive
control. Their presence was confirmed using the anti-CD68 monoclonal antibody PGM 1 in a
subset of 5 diverticulitis samples. Since obvious negative tissues are not described the same
(placental) tissue was used as a negative control. Specimen handling was identical, except appli-
cation of the primary antibody.
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Histological analysis
Breast cancer and ovarian cancer. TMA cores were considered representative if they con-
tained more than 25% tumor.
Patient samples were included if 2 or 3 samples were considered representative.
All TMA’s and slides were graded for FR-β staining (0 = no staining; 1 = weak staining
(Fig 1A); 2 = moderate staining (Fig 1B); 3 = strong staining (Fig 1C)) when at least 25% of the
core consisted of tumor cells. The scoring was performed according to previously published
studies [2,4]. After judging of the cores separately, a mean score was appointed to each patient
sample (consisting of four cores) based on the overall staining intensity observed in the sample.
Colorectal cancer and diverticulitis. Colorectal cancer samples and diverticulitis samples
were scored based on the dominant staining intensity. Finally, for statistical purposes, all cases
were divided into a ‘negative staining’ group (score 0) and a ‘positive staining’ group (score 1,
2 or 3). Scoring was performed by the researchers (LMAC, EDB, PK) after training by an expe-
rienced pathologist (JB), and all samples were confirmed by the pathologist. Scores were com-
pared, and in cases of different grading, discussed until consensus was met.
In this study, the colorectal cancer cases showed expression of FR-β in a subset of tissue
macrophages. To elucidate whether this was a tumor-specific phenomenon, and therefore an
interesting target for colorectal cancer specific optical imaging, an additional set of diverticulitis
samples (n = 25) were stained to evaluate the presence of FR-β on inflammatory associated
macrophages.
Statistical analysis
All statistical analyses were performed by using SPSS 21.0 (SPSS Inc, Chicago, IL, USA).
Descriptive statistics were calculated for variables of interest. The Chi-square test was applied
to analyze correlations between FR-β staining and several disease-related variables. Survival
analyses were performed for ovarian cancer and breast cancer. Due to small numbers, survival
could not be calculated for colorectal cancer. Overall survival was defined as the time from
diagnosis until the last follow-up while alive or death due to the tumor (ovarian or breast,
respectively). Progression-free survival was defined as the time from primary surgery until
progression of the disease, recurring disease or last follow-up. Survival curves were generated
using Kaplan-Meier analysis. The prognostic influence of FR-β expression was tested in a Cox
proportional hazards model. P-values<0.05 were considered statistically significant.
Image capture
The images shown in this paper were acquired using a Leica DM4000B microscope and a Leica
DFC450 digital camera (Leica Microsystems GmbH, Wetzlar Germany).
Results
Validation staining technique
Strong staining was shown to be present in the placental villous stroma (Fig 2A). Staining was
shown to co-localize with the so-called Hoffbauer cells, which are considered specialized mac-
rophages, known to express FR-β. Staining with the secondary antibody only demonstrated
absent staining (Fig 2B). Furthermore, the anti-CD68 macrophage staining (Fig 2C) was
shown to accurately co-localize with the FR-β stain (Fig 2D), validating specificity and immu-
noreactivity of the anti-human FR-β antibody.
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Ovarian cancer
Patient characteristics. Baseline patient characteristics of the 339 patients included in the
database are shown in Table 1 and are summarized here. Histology was known in 326 of 339
Fig 1. FR-β expression in representative samples. A: weak expression (staining intensity 1). B: moderate
expression (staining intensity 2). C: strong expression (staining intensity 3).
doi:10.1371/journal.pone.0135012.g001
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Fig 2. Validation anti-human FR-β specificity and immunoreactivity. A: Strong staining was appreciated
in the placental villous stroma known to express FR-β, validating anti human FR-β binding specificity and
immunoreactivity B: Absent staining was shown after staining with the secondary antibody only. Co-
expression of the C: anti-CD68 stain and D: FR-β in activated macrophages in a diverticulitis sample
validated anti-human FR-β specificity and immunoreactivity.
doi:10.1371/journal.pone.0135012.g002
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cases. The total number of tumor samples obtained from these 326 patients was 386 (primary
surgery n = 295, interval debulking surgery n = 63 and surgery for recurrent disease n = 28).
The majority of tumors consisted of serous carcinoma (n = 198; 58.4%), followed by endome-
trioid (n = 49; 14.5%) and mucinous adenocarcinoma (n = 38; 11.2%). More than seventy per-
cent of tumors were classified as FIGO stage III or IV (n = 243; 71.7%).
FR-β expression. Representative FR-β staining was obtained in all 339 patient samples
included in our study of which almost 80% showed no FR-β expression at all (n = 269; 79.4%),
Table 1. Characteristics ovarian cancer patients.
N = 339
Age (mean, min-max, SD) 57.4 16–89 13.2
Age; grouped n %
<58 years old 158 46.6
 58 years old 180 53.1
Missing 1 0.3
Tumor type n %
Serous adenocarcinoma 198 58.4
Other 106 31.3
- mucinous adenocarcinoma 38 11.2
- endometrioid adenocarcinoma 49 14.5
- clear cell carcinoma 18 5.3
- undifferentiated 1 0.3
Missing 35 10.3
FIGO-stage n %
Stage I 66 19.5
Stage II 28 8.3
Stage III 192 56.6
Stage IV 51 15.0
Missing 2 0.6
Tumor differentiation grade n %
Grade I 55 16.2
Grade II 91 26.8







Progression free survival (months)
(mean, min-max, SD) 29.6 0–207 36.3
Overal survival (months)
(mean, min-max, SD) 54.0 0–134 33.0
Residual disease n %
< 2 cm 157 46.3
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18.6% (n = 63) showed weak staining and only 2.1% (n = 7) showed moderate staining (Fig
3A). None of the samples showed strong staining.
FR-β expression was evaluated in regard to known risk factors in ovarian cancer; e.g. grade
of differentiation, FIGO stage, histological subtype (serous vs. non-serous), age (<58 vs.58)
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and residual disease2 cm. None of these factors showed a significant correlation to FR-β
status.
In a previous study, FR-α expression was analyzed using the same tumor samples and data-
base [2]. The correlation found in the present study between FR-α and FR-β expression was
weak, but not significant (p = 0.098).
Survival analysis. All of the above factors were associated with reduced progression free
survival (PFS) and overall survival (OS). In multivariate regression analysis, the only significant
predictors of both PFS and OS were FIGO stage III-IV (p<0.0001), residual tumor>2 cm
(p<0.0001) and serous histology (p = 0.045). FR-β expression did not show any correlation
with either PFS or OS.
Breast cancer
Patient characteristics. Baseline patient characteristics of all 418 patients included in the
database are presented in Table 2 and will only be summarized here. All patients were female,
of whom 48.1% were 59 years of age. Mean tumor size was 22.7 mm (1–140 mm). Ratios of
breast-conserving surgical therapy and mastectomy were nearly equal (50.7% and 49.0%,
respectively); 63.4% of patients received adjuvant radiotherapy and 49.5% received adjuvant
chemotherapy. Nearly all tumors were diagnosed as either invasive ductal carcinoma (50.8%)
or invasive ductal carcinoma with ductal carcinoma in situ (42.3%).
FR-β expression. FR-β scores could be obtained in all 418 cases included in our study.
The vast majority of tumor samples showed no FR-β staining (n = 381; 91.1%), whereas 36
samples (8.6%) showed weak staining and only 1 sample (0.002%) showed moderate staining
(Fig 3B). For statistical analyses, weak and moderate scores were combined into an ‘FR-β posi-
tive’ group, as compared to the ‘FR-β negative’ group. Low rates of positive staining were
observed in invasive ductal carcinoma (n = 20; 4.8%). There was no FR-β staining in other his-
tological subtypes.
FR-β expression showed no significant correlation to age, differentiation grade, tumor size,
relapse rate or HER2-neu status. Interestingly, axillary status showed a significant correlation
with FR-β, with a higher expression rate in negative axillary lymph nodes compared to positive
nodes (p = 0.022)(Table 2).
Survival analysis. In a multivariate regression analysis, differentiation grade III
(p = 0.009) was the only significant predictor for overall survival. A trend was observed for pos-
itive axillary status (p = 0.080). Predictors for progression free survival were high differentia-
tion grade (p = 0.005), positive axillary status (p = 0.024) and positive progesterone receptor
status (p = 0.017). FR-β status showed no correlation to either OS or PFS.
Colorectal cancer
Patient characteristics. Twenty tumor samples were stained for FR-β, all obtained during
cytoreductive surgery for colorectal cancer combined with hyperthermic intraperitoneal che-
motherapy (HIPEC). Of these, thirteen were female and seven were male, and the mean age
was 54.6 (range 34–75). Tumor differentiation was good in six patients, moderate in six
patients and poor in eight patients. There were twelve mucinous adenocarcinomas, seven intes-
tinal type adenocarcinomas and one singlet cell carcinoma.
FR-β expression. Eleven of 20 (55%) tumor samples stained positive for FR-β: however,
staining intensity was variable, ranging from weak to faintly visible (Fig 3C). Of the eleven pos-
itive samples, six tumors were classified as mucinous adenocarcinoma (50% of total number of
this tumor subtype) and five were intestinal type adenocarcinoma (71% of total number of this
tumor subtype). Most staining was seen at the apical side of the tumor cells. In addition, tissue
Folate Receptor-Beta Expression
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macrophages showed expression of FR-β. In the surrounding adipose tissue, weakly positive
staining was seen in one sample, while no expression was observed in fifteen samples. All blood
vessels were negative. Six samples contained smooth muscle cells, of which one sample scored
positive and five scored negative. Healthy intestinal epithelium stained weakly positive in five
samples. Two samples contained ovarian tissue, and both were negative for FR-β. The small
number of samples did not allow for survival analyses.
Diverticulitis
Patient characteristics. Seventeen of 25 patients included were female (68%). The mean
age of all patients was 64 (range 29–86). Most patients underwent a sigmoid resection because
of diverticulosis or suspected malignancy. One patient needed surgery because of widespread
endometriosis.
Table 2. Characteristics breast cancer patients.
N = 418
Age (mean, min-max, SD) 59.7 27–91 13.8
Treatment interventions n %
Breast-conserving surgery 212 50.7
Mastectomy 205 49.0
Adjuvant radiotherapy 265 63.4
Adjuvant chemotherapy 207 49.5
Age; grouped n %
<59 years old 217 51.9
59 years old 201 48.1









(mean, min-max, SD in mm) 22.7 1–140 18.0
Tumor differentiation grade n %
Grade I 105 25.1
Grade II 180 43.1
Grade III 131 31.3
Missing 2 0.5





(mean, min-max, SD) 50.6 0–134 33.0
Overall survival(months)
(mean, min-max, SD) 54.0 0–134 33.0
doi:10.1371/journal.pone.0135012.t002
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FR-β expression. Of the 25 diverticulitis samples, 20 (80%) stained positive, of which
moderate or strong FR-β expression was seen in nine samples (45%), and weak expression in
eleven samples (55%). FR-β staining was shown to co-localized predominantly with the macro-
phages. The five negative samples were diagnosed as a submucosal abcess, non-active colitis,
endometriosis with a few diverticula, and, in two cases, active diverticulitis.
Discussion
The aim of this study was to evaluate the expression of the FR-β in ovarian, breast and colorec-
tal cancer. In summary, FR-β expression was low or absent in almost all tumor samples of
ovarian, breast and colorectal cancer, with staining seen in 21%, 9% and 55%, respectively. Fur-
thermore, FR-β status showed no association with either OS or PFS in ovarian and breast
cancer.
Several studies report FR-β expression in myelogenous leukemias of hematopoietic origin
[17,18]. Sega et al reported FR-β expression on a variety of solid tumors of diverse origins [6].
Conversely, our data show low or absent FR-β expression in most of the investigated ovarian,
breast and colorectal tumor samples.
Previously, FR-α expression in ovarian cancer was analyzed using the same tumor tissue
samples and database [2]. No significant correlation could be detected between the FR-α and
FR-β expression (p = 0.098). FR-β expression was also evaluated in regard to known risk factors
in ovarian and breast cancer. None of the known risk factors for ovarian cancer showed a sig-
nificant correlation to FR-β status. Likewise, FR-β expression showed no significant correlation
to most known risk factors for breast cancer. Axillary status was the only factor that showed
significant correlation to FR-β expression. A higher FR-β expression rate was seen in the tissue
microarrays (TMAs) of breast cancer patients with negative axillary lymph nodes compared to
positive nodes (P = 0.022). A careful hypothesis might be that FR-β expression could be used as
prognostic biomarker to indicate long-term outcome of breast cancer patients. However, the
overall low expression rate of only 9% hampers further conclusions. The transmembrane folate
receptor (FR) expressed by cancer cells, in particular the alpha subtype, has proven to be a use-
ful target for non-invasive diagnostic imaging and therapy [2,7]. From the present study we
conclude that the low FR-β expression in ovarian and breast tumor tissue implies little practical
use of this receptor in diagnostic imaging and for therapeutic purposes.
The relationship between inflammation and cancer is widely appreciated [19]. Chronic
inflammation is thought to increase the risk of cancer and activated macrophages contribute to
a worse prognosis by enhancing matrix degradation and metastasis [20,21]. Our results dem-
onstrated that colorectal cancer cases showed expression of FR-β in a subset of tissue macro-
phages. However, since 80% of the diverticulitis samples also demonstrated FR-β expression in
a comparable amount of the macrophages, this indicates that FR-β positivity in tissue macro-
phages near an infiltrative tumor is not a tumor-specific phenomenon. Therefore, FR-β stain-
ing in tissue macrophages is probably not useful to discriminate between an inflammatory
process and a malignant neoplasm.
Conclusions
FR-β expression was low or absent in the majority of ovarian, breast and colorectal tumor sam-
ples. From the present study we conclude that the low FR-β expression in tumor tissue implies
limited practical use of this receptor in diagnostic imaging and therapeutic purposes in ovarian,
breast cancer and colorectal cancer. In addition, these findings do not support the possibility
that FR-β could be used as a target to discriminate between colorectal cancer and diverticulitis.
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